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Lysyl oxidase (LOX), a promising therapeutic target for the progression of cancer and fibrosis, has not been well 
characterized yet. A major difficulty faced in LOX characterization is its lack of solubility in common buffers. In this study, 
mature LOX (mLOX) was cloned, purified and its purity was ascertained by mass spectroscopy. Through screening various 
buffers, 0.2 M glycine-NaOH buffer with 10% glycerol pH 8.0 was identified to maintain mLOX in its soluble state. About 
67% of the refolded mLOX was found to be in copper bound state after His-tag removal. Catalytic properties Km and kcat 
were found to be 3.72 × 10−4 M and 7.29 ×103s−1. In addition, collagen cross-linking in ARPE-19 cells was augmented on 
exposure to mLOX, endorsing its biological activity. Circular Dichroism revealed that mLOX comprises 8.43% of α-helix 
and 22% of β-strand and it was thermally stable up to 90°C. Disulfide linkage imparts the structural stability in LOX which 
was experimentally ascertained with intrinsic and extrinsic fluorescence studies.  
Keywords: Enzyme kinetics, Recombinant mLOX, Spectroscopy and structure stability 
LOX belongs to the copper-dependent amine oxidase 
family (EC number, 1.4.3.13) and has copper and 
lysine tyrosyl quinine (LTQ) as its cofactors. LOX 
pro-enzyme with a molecular weight of 50 kDa is 
secreted extracellular, where it is proteolytically 
cleaved by bone morphogenetic protein-1 into a 
catalytically active mature LOX of 32 kDa and a 
propeptide of 18 kDa
1
. LOX enzyme is responsible 
for the maturation of elastin and collagen by 
converting peptidyl lysine of the monomers into 
allysine and hence it is crucial for the formation of 
extracellular matrix (ECM)
2
. LOX, being a key player 
in the formation and preparation of ECM, its 
expression and activity are altered in ECM related 
diseases
3
. In addition to the role in cross-linking, LOX 
is also implicated in the progression of cancer. Its role 
in cancer has been validated in cell migration
4
 and in 
tumour metastasis
5
. Expression of LOX enhances  
epithelial-to-mesenchymal transition (EMT) in 
cancerous condition by down regulating the cell 
adhesion molecule E-cadherin
6
. LOX enhance the 
tumour endothelial migration and angiogenesis via Akt 
pathway under the stimulation of VEGF/hypoxia
7,8
. 
Though mature LOX function as pro-angiogenic,  
N-terminal region of LOX is designated as pro-peptide 
and is known for its anti-angiogenic function
9,10
. From 
our group, we have shown the over expression of LOX 
pro-peptide in the endothelial cell inhibits 
angiogenesis
11
. Nevertheless, LOX is identified as a 
prognostic factor
12
 and also a biomarker
13
 in several 
cancerous conditions. Apart from cancer, aberrant 
expression of LOX has been reported as a diagnostic 
marker in fibrosis where the inhibition of its activity 
combats the fibrotic condition
14,15
. It has also been 
hypothesized that inhibition of LOX activity may be a 
possible way to reduce the stiffening of the trabecular 
meshwork in glaucoma
16,17
. Inhibiting the expression of 
LOX with βAPN, a known inhibitor for LOX, is shown 
to reduce the disease pathogenesis. However, lack of 
specificity of βAPN makes it a poor drug. Although the 
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importance of targeting LOX in cancer
3
 and other 
diseases like fibrosis
18
, glaucoma
19
 andcardiovascular 
diseases
20
 has been well discussed, effective drugs are 
not available. 
Conventional drug development for LOX is not 
possible because of the lack of its crystal structure. 
Further, studies on the structure of LOX and its 
stability are also limited. In aqueous buffers, LOX 
exhibits low solubility and aggregation, which 
remains an obstacle in its structural and functional 
characterization. In our previous study, we have 
reported LOX model using ab initio modelling with 
proper copper geometry by in silico approach
21
. Here, 
we endeavour to characterize the LOX enzyme by  
in vitro approach.  
In this study, recombinant human mature LOX 
(mLOX) was purified and characterized. Recombinant 
mLOX was refolded into biological active enzyme in 
aqueous buffer devoid of urea. Biochemical properties 
such as optimal substrate concentration, pH and 
enzyme kinetics were identified and biological activity 
was substantiated with cell culture experiments. 
Thermal stability and secondary structure of mLOX 
were studied using CD spectra, intrinsic and extrinsic 
protein fluorescence experiments.  
 
Materials and Methods 
Construction, expression and purification of pQE-30Xa+mLOX 
expression plasmid 
Human mLOX was cloned into pQE-30Xa vector 
between the Stu I and Hind III sites, as described in 
our previous report
22
. In brief, the mLOX gene was 
amplified from Human Umbilical Vein Endothelial 
Cells (HUVECs) cDNA (template) using the gene-
specific primers Stu I 5GGTATCGAGGGAAGGCC 
TGACGACCCTTACAACCCC3 and Hind III 
5TCAGCTAATTAAGCTTCTAATACGGTGAAAT
TGT3. Using an infusion enzyme kit (Cat # 638909, 
Takara, Clontech, USA), pQE-30Xa+mLOX 
expression vector was constructed from the linearized 
vector and amplified mLOX DNA by following the 
manufacturer’s protocol. pQE-30Xa+mLOX encodes 
the mLOX with six histidine residues (His tag) at the 
N-terminal linked through factor Xa cleavage site. 
Recombinant mLOX was expressed in M15 (pREP4) 
strain of E. coli from the transformed plasmid  
pQE-30Xa+mLOX. Transformed colonies were 
grown in Luria-Bertani broth containing 0.1 µg/mL of 
ampicillin and 0.025 µg/mL of kanamycin at  
37°C. The culture at mid-log phase (absorbance unit 
0.5-0.7 at 600 nm) was induced with 1 mM  
isopropyl-β-D-thiogalactopyranoside (IPTG) for 
expression of mLOX and was cultured for 4 h  
at 30°C. E. coli cells were pelleted down by 
centrifugation and re-suspended in lysis buffer  
(50 mM sodium dihydrogen phosphate, 300 mM 
sodium chloride, 8 M urea and protease inhibitor 
cocktail at a concentration of 1 mg/mL, pH 8.0). 
Suspension was incubated for 30 min at 4°C and the 
whole cell including inclusion bodies was lysed by 
sonication. Then the lysate was centrifuged at 12857 g 
for 30 min at 4°C and purification was carried out 
with the supernatant. The clarified supernatant was 
passed through the Ni-NTA affinity column 
equilibrated with lysis buffer. Non-specifically bound 
proteins were removed by stringent washing with  
30 mM imidazole in lysis buffer and then His-tagged 
mLOX protein was eluted with lysis buffer containing 
250 mM imidazole. The purity of the recombinant 
protein was confirmed by SDS-PAGE, western blot 
(LOX antibody, Cat # SC-32409, Santa Cruz 
Biotechnology and His tag antibody, Cat # 2365,  
Cell Signaling Technology,) and mass spectroscopy 
(MS). Protein estimation was done by using  
Pierce Coomassie plus protein assay kit (Bradford) 
(Cat # 23236, Thermo Fisher Scientific). 
 
Mass spectroscopy (MS) analysis 
Recombinant mLOX (1 µg) was suspended in  
50 µL of 50 mM ammonium bicarbonate buffer,  
pH 9.0. Disulfide bonds were reduced using 
dithiothreitol (DTT) with the final concentration of  
10 mM (60°C for 15 min) and alkylated with 
iodoacetic acid with the final concentration of 20 mM 
RT for 30 min. Trypsin 50 ng (Sigma proteomics 
grade, Cat # T6567) was added to the sample and 
digested for overnight at 37°C; digestion was stopped 
by adding 1 µL of 1% formic acid. Then excess  
salts were removed by Oasis HLB cartridge  
(Cat # WAT094225, Waters Corporation, USA) 
following manufacturer's protocol. Digested peptides 
were separated in nano UPLC and analysed with 
hybrid mass spectrometry (Xevo G2S QT of mass 
spectrometry coupled with Acuity nano LC, Waters, 
USA). The detected peptides were matched against 
UniProt human protein database using Protein Lynx 
Global Software (PLGS, version 2.5.3, Waters, USA) 
and identified the protein. 
 
Screening for the buffer to maintain mLOX in solution 
Optimum solubility screening is a systemic way to 
determine the solubility of a protein.A known amount 
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of the protein of interest will be re-suspended in 
various buffers with chemical additives and solubility 
will be checked by protein estimation after high-speed 
centrifugation in supernatant and pellet
23
. For 
crystallization studies, this approach is being followed 
to identify optimal buffer for protein solubility and 
stability. This approach was employed to identify 
buffer that would solubilize recombinant mLOX. 
Screened the following buffers: 10 mM dipotassium 
hydrogen phosphate buffer, 0.2 M HEPES-NaOH 
buffer, 0.2 M Tris-HCl buffer, 0.2 M borate buffer,  
0.2 M arginine-NaOH, 0.2 M glycine-NaOH buffer 
over the pH range of 6-9. Glycerol, a co-solvent 
known to increase the protein stability, was added to 
the buffers up to a final concentration of 10%. In 
brief, purified mLOX protein was suspended in equal 
volume of above–tested buffers to the final 
concentration of 50 μg/150 μL and incubated at RT 
for 30 min. The solubility was checked by visible 
aggregation and further centrifuged at 10000 g for  
10 min to identify any aggregation. Further, protein 
estimations were done in both the pellet and the 
supernatant.  
 
Refolding of mLOX 
Step-wise reduction in the denaturant concentration 
was implemented to refold mLOX. The rate of protein 
folding to its native structure increase by a step-wise 
reduction in the denaturant concentration
24
. 
Recombinant mLOX was refolded by a stepwise 
reduction in urea concentration. Purified mLOX was 
suspended and dialyzed against the identified buffer 
for 8 h using 3 kDa semi-permeable membrane and 
urea concentration was varied from eight molar to 
zero molar (in steps of 1 M difference/step). After 
refolding, His tag was removed from the mLOXusing 
factor Xa endoprotease (Cat # 33223, Qiagen, Hilden, 
Germany) in the presence of 1 mM calcium chloride 
reconstituted in the glycine-NaOH buffer at the pH of 
8.0 at 37°C for overnight. After digestion, factor Xa 
protease was removed using factor Xa removal resin 
(Cat # 33213, Qiagen) following the manufacturer’s 
protocol. Subsequently, undigested His tag protein 
was captured using Ni-NTA affinity column, while 
His tag free mLOX was collected as unbound protein. 
Complete removal of His tag was confirmed by 
western blot using His tag specific antibody.  
 
Incorporation and estimation of copper in recombinant 
mLOX 
His tag free mLOX was dialyzed against a glycine-
NaOH buffer with copper (Cu) (2:1, Cu:protein 
concentration) for 4 h. Then free/unbound Cu was 
removed by dialysis against glycine-NaOH buffer free 
of Cu for 16 h. Cu bound to the recombinant mLOX 
was estimated by atomic absorption spectroscopy (A 
Analyst 7000, Perkin, USA). The instrument was 
calibrated with 0.2%  
nitric acid and background values for solvents  
(Milli-Q water and buffer) were determined and taken 
into account during calculation. Absorption of the 
known concentrations (2.5, 5, 7.5 and 10 μg/mL) of 
elemental copper was used as standards. mLOX  
(100 μg/100 μL) was reconstituted to 1 mL using 0.2% 
nitric acid and Cu was atomized at 2300°C using 
graphite furnace system and estimated at 324.8 nm 
using a hollow cathode lamp. Absorbance values were 
recorded thrice and the mean values were used for 
calculation
25
.  
 
LOX activity assay 
LOX catalytic activity was measured based on the 
rate of deamination of 1,5-Diaminopentane (DAP) 
through detecting the amount of hydrogen peroxide 
(H2O2) released in the reaction. Liberated H2O2 oxidize 
amplex red into fluorescent resorufin at 1:1 ratio in the 
presence of enzyme hydrogen peroxidase. Assay 
protocol as follows, to 100 μL reaction mixture [0.15 M 
boric acid and 0.12 M sodium chloride pH 8.2, 50 µM 
N-acetyl-3,7-dihydroxyphenoxazine (Amplex Red, 
Molecular Probes, Invitrogen, USA), 0.1 Unit/mL 
horseradish peroxidase (HRP, Cat # P8375, Sigma) 
and 10 mM DAP (Cat # C8561, Sigma)], 100 ng of 
purified mLOX enzyme was added and the total 
reaction volume was 200 μL. All experiments were 
performed in opaque black 96 well microplate  
(Cat # 655076, Greiner bio-one) and the full protocol 
was carried out in dark environment, buffer and other 
constituents were prepared in double distilled water. 
The fluorescent end product was excited at 563 nm 
and the emission was read at 587 nm for 90 min with 
5 min intermittent reading with a spectrophotometer 
(SpectramaxM2
e
 plate reader, Molecular Devices, 
USA). Sample lacking mLOX enzyme was used to 
collect the background readings and was used for 
calculating the enzyme activity. A linearity curve for 
standard hydrogen peroxide H2O2 (0-2000 nm) was 
plotted and the enzyme activity was calculated.  
 
Determination of pH, temperature and substrate optima, 
enzyme kinetics and inhibitor studies of LOX 
Purified mLOX enzyme (100 ng) was incubated 
with buffer systems with the pH range of 6-10:  
0.1 M sodium phosphate buffer (0.1 M disodium 
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hydrogen phosphate with 0.1 M sodium dihydrogen 
phosphate,pH 6.5 and 7.5), 0.1 M borate buffer  
(0.1 M boric acid with 25 mM sodium tetraborate 
with 75 mM NaCl, pH 8 and 8.5) and 0.2 M glycine-
NaOH buffer (pH 9, 9.5 and 10). Enzyme mLOX was 
pre-incubated in respective buffers for 30 min at 37°C 
and assay were performed.Well which received only 
reaction mixture without mLOX enzyme, incubated 
with respective buffer was used for background 
corrections. The optimum temperature for mLOX 
enzyme catalytic activity was determined by  
pre-incubating the enzyme at various temperatures 
(25°C, 37°C, 50°C and 75°C) with substrate DAP. 
Recombinant mLOX 100 ng was incubated with  
100 mM of DAP for 15 min at designated 
temperatures then the reaction mixture was added and 
fluorescent reading was measured as endpoint. The 
total reaction volume was 200 µL. A blank sample 
(without mLOX) was included for respective 
temperatures and background corrections were made 
for each condition, respectively. Michaelis constant 
(Km) value of the purified enzyme was estimated for 
DAP concentration range from 0.01-0.4M. Using the 
Lineweaver-Burk plots Km, Vmax and kcatfor mLOX 
were calculated. Homocysteine (Hcys) and βAPN 
were used for inhibitor studies. Recombinant mLOX 
enzyme (100 ng) was pre-incubated with various 
concentration of inhibitors at 37°C for 5 min and 
reaction mixture containing 100 mM of DAP was 
added and enzyme activity was measured.Interference 
from Hcys was accounted cautiously as it can react 
with amplex red directly. Here, a sample with only 
reaction mixture and Hcys without mLOX enzyme 
served as the blank and the readings were used  
for background corrections. Three independent 
experiments were performed and mean ± SD values 
were represented.  
 
Immunofluorescence staining of collagen in ARPE 19 cells 
Adult Retinal Pigment Epithelial (ARPE19) cells 
(ATCC-CRL-2302) (ATCC, USA) were cultured in 
DMEM-F12 (Sigma-Aldrich, USA), 14.2 mM sodium 
bicarbonate with 10% (v/v) fetal bovine serum  
at 37C with 5% CO2. Cells were grown to  
70-80% confluence and serum starved for overnight. 
It was then treated with various concentrations  
(1 to 1000 ng/mL) of recombinant mLOX for 72 h.  
TGF-β, known to induce collagen and LOX synthesis, 
was used as positive control at the concentration of 
2.5 ng/mL. After treatment,cells were fixed with 4% 
formal dehydefor 10 min followed by 
permeabilization with 0.1% Triton-X for 5 min and 
blocked with 1% bovine serum albumin for 1 h. The 
cells were then incubated with anti-collagen primary 
antibody (Cat #PA1-36058, Thermo Fischer 
Scientific) at 1:100 dilution for overnight at 4°C 
followed by incubation with 1:700 diluted Alexa-488 
conjugated anti-rabbit secondary antibody (Cat #A-
11008, Invitrogen, Thermo Fischer Scientific). 
Images were taken using Axio Observer Z.1 
microscope with a numerical aperture of 0.55 (Carl 
Zeiss, Gottingen, Germany). Axio Vision Rel. 4.8 
software was used to analyze the images. 
 
Circular dichroism  
Circular Dichroism (CD) spectra of recombinant 
mLOX were collected using CD spectrometer 
(JASCO J-815, Tokyo, Japan) equipped with peltier 
temperature control. Throughout the experiment, 
nitrogen gas was blown into cuvette chamber to avoid 
any condensation. For all CD experiments, 
1 mg/mL of mLOX and cuvette path length of 10 mM 
was used. CD spectrum was acquired in the far  
UV-region (200-240 nm)
26
. Secondary structure was 
predicted using the K2D2 software. For CD melting 
curve experiment,the ellipticity of mLOX at 208 and 
222 nm was monitored. For the unfolding experiment, 
ellipticity was collected from 20-90°C with a step 
wise increment of 1°C. For refolding experiment, the 
temperature was decreased from 90-20°C with a 
decrement of 1°C. Ellipticity value for a buffer in the 
far UV-region was acquired and background 
correction was performed
27
.  
 
Intrinsic fluorescence of mLOX 
Tryptophan residues in mLOX were excited at  
295 nm and fluorescent emission spectra were 
recorded from 300 nm to 400 nm
28,29
. mLOX 
(3 μM) was suspended in 200 μL of 0.2 M glycine-
NaOH buffer (pH 8.0) with 10% glycerol. For 
disulfide reduction, mLOX protein was treated with 
100 mM DTT for 15 min at 60°C and then the 
spectrum was collected. For denaturation, mLOX was 
treated with 2M guanidine hydrochloride (GnHCl) for 
15 min at 37°C and the spectrum was collected.The 
total reaction volume was 200 µL. Three independent 
experiments were performed and mean ± SD values 
were represented.  
 
Extrinsic fluorescence analysis of mLOX 
Binding of 8-Anilino-1-napthalenesulfonic acid 
(ANSA) to mLOX was studied by excitation at  
370 nm and emission spectra were recorded from  
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400 to 600 nm
30. mLOX (3 μM) was treated with 
ANSA in 1:100 ratio and incubated at 37°C for  
30 min and the spectrum was obtained. Total reaction 
volume was 200 µL. Experiments were performed in 
triplicate and mean ± SD values were represented. 
 
Results  
Construction of pQE-30 XA + mLOX plasmid 
PCR amplified mLOX product was inserted into 
the pQE-30 Xa plasmid and the plasmid was 
transformed into M15 (pREP4) E. coli. The plasmid 
was isolated from the positive clones and was 
confirmed by restriction digestion. Thus, the 
transformed M15 (pREP4) E. coli contained the 
complete pQE-30 Xa + mLOX construct (Fig. 1A). 
DNA sequencing confirmed that the inserted LOX 
sequence was free of any mutation. 
 
Purification and confirmation of recombinant mLOX 
Transformed bacterial cells upon induction with 
IPTG expressed mLOX, which was purified using  
Ni-NTA affinity column. Purified fraction showed a 
single band at 29 kDa (Fig. 1B), corresponding to the 
molecular weight of mLOX. The purification yield 
was about 15 mg/L of broth.Western blot analysis 
revealed a single band at 29 kDa when probed using 
both LOX and His tag as shown in our previous 
report
22
, which confirms the purity of purified 
 
 
Fig. 1 — Plasmid construction, expression, purification and confirmation of mLOX. (A) pQE-30Xa+mLOX plasmid construct diagram 
(adapted and modified from Qiagen manual); (B) Silver-stained 10% SDS-PAGE gel showing the Ni-NTA affinity purification. Lane 1: 
Molecular size marker; Lane 2: Crude cell lysate; Lane 3: Ni-NTA unbound fraction; Lanes 4-6: fractions from 30 mM imidazole wash  
1-3; Lanes 7-14: 250 mM imidazole eluted fraction from 2 to 8; (C) MS spectrum of a peptide derived from tryptic digestion of 
recombinant mLOX. The value on each peak denotes the m/z ratio of the peptide; and (D) Peptide map of mLOX identified by MS 
analysis. The intensity of the colour is based on the abundance of each peptide 
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recombinant mLOX. Mass spectrum of peptides 
derived from the purified recombinant mLOX 
(Fig. 1C) was analysed with PLGS, which showed a 
single hit for human LOX (UniProt ID p28300) with 
peptide coverage of 85% for mature LOX sequence. 
Peptides identified by MS analysis were within the 
mature LOX sequence (Fig. 1D), which indicates that 
recombinant mLOX preparation was pure.  
 
Refolding of recombinant mLOX 
In order to refold the purified mLOX, various 
buffers were screened (Table 1). Among them, 
glycine-NaOH buffer with 10% glycerol pH 8.0 
showed no aggregation whereas rest of the screened 
buffers resulted in aggregation of recombinant 
mLOX. Recombinant mLOX was refolded by 
stepwise reduction in urea concentration by dialysis 
against this buffer. The dialysate was inspected for 
protein aggregates by centrifugation (10000 g for  
30 min) at the end of each buffer change, which again 
revealed no aggregate in the glycine-NaOH buffered 
sample. Thus, the optimised buffer was used for 
further mLOX analysis. Using factor Xa endoprotease, 
His tag was cleaved from the refolded mLOX with 
70% efficiency. Cleavage was confirmed by western 
blot analysis against LOX and His tag antibody, this 
data has been shown in our earlier report
22
. 
 
Estimation of copper in recombinant mLOX 
From the standard copper concentration, it was 
calculated that 67 ± 2.8% of recombinant mLOX was 
found in the copper bound state.  
 
Substrate specificity and effect of pH and temperature on 
recombinant mLOX activity 
Enzymatic action of recombinant mLOX (100 ng) 
was tested against natural substrates; elastin, collagen 
and pseudo substrate DAP. With increasing 
concentration of DAP the enzymatic activity 
increased (10 mM: 1.15 ± 0.4 nmol of H2O2 
released/min and 100 mM: 4.7 ± 0.4 nmol of H2O2 
released/min) whereas, mLOX showed lesser activity 
against elastin and collagen (elastin 100 μg:  
1.59 ± 0.7 nmol of H2O2 released/min and collagen  
100 μg: 1.37 ± 0.4 nmol of H2O2 released/min) even 
at higher concentration (Fig. 2A). Recombinant 
mLOX was incubated with various buffer systems 
with pH ranging from of 6.5 to 10 and the enzymatic 
activity was evaluated. Optimal enzyme activity was 
found to be at the pH 8 (Fig. 2B). The catalytic 
activity was found to be decreased at acidic (<7) and 
more basic pH (>8.5) condition. Dependence of 
reaction-rate of mLOX on temperature was evaluated 
by assessing its activity under various temperatures 
(25°C, 37°C, 50°C and 75°C). Interestingly, the 
catalytic action of mLOX increased with increasing 
temperature (Fig. 2C). The temperature stability of 
mLOX was assessed from a structural aspect (CD 
spectra, intrinsic and extrinsic protein fluorescence) in 
the following sections. 
 
Kinetics analysis of mLOX 
Effect of varying DAP concentration on 
recombinant mLOX activity was evaluated. With the 
Lineweaver-Burk plot (Fig. 2D), Km of recombinant 
mLOX for DAP was calculated to be 3.72 × 10
−4
 M, 
estimated Vmax was 1.25 Units/mg of mLOX 
(Units = µmoles of H2O2s
−1
) and kcat of 7.29 × 10
3 
s
−1
. 
With this, we calculated the catalytic efficiency 
(kcat/Km) of mLOX and it was found to be 1.96 ×  
10
7 
M
−1 
s
−1
. 
 
The biological activity of recombinant mLOX 
Collagen is one of the endogenous substrates  
for LOX and it augments the cross-linking of 
collagen. Staining of collagen in mLOX treated 
ARPE19 cells revealed long and thick bundles of 
collagen. Control cells (Fig. 3A) didn’t show  
collagen fibre staining but cells treated with TGF-β 
(Fig. 3B) showed collagen fibre staining pattern  
and served as the positive control. When cells were 
treated with mLOX, collagen fibre staining increased 
with the increasing concentration of mLOX  
(Fig. 3C-F). The staining pattern of cells with  
1000 ng/mL of mLOX (Fig. 3F) was comparable 
with TGF-β treated cells (Fig. 3B). Thus,  
recombinant mLOX was observed to be biologically 
active. 
Table 1 — Screening of various buffers for recombinant  
LOX solubility 
Buffer Visible 
aggregation 
Check 
Centrifugation  
at 10000 rpm  
for 10 mins 
Protein conc. in 
supernatant 
compared to the 
original conc. 
HEPES-NaOH 
buffer 
Aggregated Pelleted 10% 
Tris-HCl Buffer Aggregated Pelleted 1% 
Potassium 
phosphate buffer  
Aggregated Pelleted 20% 
Borax – Boric 
acid buffer 
No 
aggregation 
Small pellet 50% 
Arginine- NaOH 
buffer,  
Aggregated Pelleted 10% 
Glycine – NaOH 
buffer 
No 
aggregation 
No pellet 95% 
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Fig. 2 — Enzymatic characterization of mLOX. Recombinant mLOX (100 ng) and reaction mixture were treated at respective conditions 
(as described in materials and methods) and readings were taken fluorometrically (Excitation 563 nm; Emission 587 nm).  
(A) Comparison of enzymatic activity of mLOX upon various substrates; (B) Effect of pH on recombinant mLOX activity; (C) Effect of 
temperature on recombinant mLOX activity; and (D) Lineweaver-Burk plot of recombinant mLOX for DAP substrate 
 
 
 
Fig. 3 — Biological activity of mLOX in ARPE-19 cells. (A) Cells received only basal media served as control; (B) Cells exposed to 
TGF-β (2.5 ng/mL) served as a positive control; and (C-F) Cells exposed to various concentrations of recombinant mLOX (1, 10, 100 & 
1000 ng/mL). All images were acquired with 10X objective. Arrow indicates stained collagen fibres 
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Validation of inhibitors using recombinant mLOX 
Enzymatic activity of the recombinant mLOX was 
assessed with inhibitors such as βAPN and Hcys by 
amplex red assay using DAP as substrate. Enzymatic 
activity of recombinant mLOX was inhibited up to 
50% by Hcys at 30 μM concentration (Fig. 4A) 
whereas βAPN showed only 20% of enzyme 
inhibition at a much higher concentration of 400 μM 
(Fig. 4B). These results clearly indicate that Hcys 
inhibits mLOX better than βAPN. 
 
Far UV-CD spectrum analysis of recombinant mLOX 
The mLOX suspended in 0.2 M glycine-NaOH 
buffer (pH 8.0) with 10% glycerol showed α-helix of 
8.43% and β-strand of 22% (Fig. 5A). Melting 
experiment of mLOX was performed using 50 mM 
glycine-NaOH buffer (pH 8.0) with 1.5% glycerol, to 
avoid interference. In the melting curve study, the 
degree of ellipicity at 222 nm and 208 nm was found 
to be unaltered in the unfolding (20-90°C) and 
refolding experiment (90-20°C) (Fig. 5B & C). This 
shows that mLOX maintains its secondary structure 
till 90°C and is resistant to higher temperature. 
 
Tryptophan fluorescence emission of DTT-reduced 
recombinant mLOX 
Recombinant mLOX gave heterogenous tryptophan 
emission peaks, one peak with the maximum quantum 
yield at 304 nm and another small peak at 333-335 nm. 
 
 
Fig. 4 — Enzyme activity of mLOX on DAP in the presence  
of inhibitors. (A) Inhibition of mLOX activity by βAPN; 
(B) Inhibition of mLOX activity by Hcys. One hundred 
nanograms of recombinant mLOXand 100 mM of DAP were  
pre-incubated at 37°C for 5 min with a respective concentration of 
inhibitors and reaction mixture was added and readings were 
taken fluorometrically (Excitation 563 nm; Emission 587 nm) 
 
 
Fig. 5 — Far-UV CD spectrum of mLOX. Recombinant mLOX 
(1 mg/mL) was suspended in 200 mM glycine-NaOH buffer  
(pH 8.0) with 10% glycerol. (A) Spectrum was collected from  
200 nm to 240 nm thrice and the cumulative average was taken 
finally; (B & C) CD melting curves, monitored ellipticity at  
208 and 222 nm. The solid line represents unfolding condition  
(20 to 90°C) and dotted line represent refolding condition  
(90 to 20°C). mLOX was suspended in 50 mM glycine-sodium 
hydroxide buffer (pH 8.0) with 1.5% glycerol 
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Heterogenous peaks might be due to the localization 
of tryptophan at the varied environment. Upon 
reduction of disulfide bonds, emission peak at 304 nm 
showed a red shift to 308 nm and fluorescence intensity 
reduced with increasing DTT from 20 to 100 mM. The 
emission spectra at 333 nm was undisturbed upon 
reduction with DTT (Fig. 6A).  
 
ANSA binding analysis of reduced and denatured 
recombinant mLOX 
ANSA is a chemical molecule which binds to the 
exposed hydrophobic patches in a protein surface
30
. 
Recombinant mLOX showed an emission maximum at 
450 nm. The DTT (100mM) reduced mLOX showed a 
red shift in the emission maxima from 450 to  
470 nm, which shows the unfolding of the 
recombinant mLOX. Recombinant mLOX denatured 
with 2M GnHCl did not show much change in the 
emission spectra. When recombinant mLOX was 
reduced with DTT (100 mM) and denatured with 
GnHCl (2 M) the emission spectra showed a shift in 
the emission maxima to 470 nm and an increase in the 
fluorescence value from 250 RFU to 400 RFU. This 
shows that unfolding leads to exposure of a more 
hydrophobic region of the mLOX, which resulted in 
increased binding of ANSA (Fig. 6B).  
 
Discussion 
We report the characterization of recombinant 
mLOX using a glycine-NaOH buffer which maintains 
mLOX in its solubilised form even without urea. Here 
we demonstrated that purified mLOX is biologically 
active and thermally stable. Thermo-stability of 
mLOX is attributed to its disulfide linkage. 
Recombinant mLOX has been purified using 
infusion cloning method. Purification yield was up to 
15 mg/L of LB broth, which was higher than the 
earlier reports
31,32
. Characterization of LOX is 
challenging because of the non-availability of buffers 
that would maintain LOX in its solubilised state. An 
earlier report
31
 indicated solubility of LOX in 10 mM 
potassium phosphate buffer but in the present study, 
mLOX got precipitated in the same. Therefore, it was 
necessary to screen various buffers which maintain 
the protein without aggregation. Among the various 
buffers screened, the glycine-NaOH buffer with 10% 
glycerol pH 8.0 was identified as an ideal buffer. 
Presence of glycine and glycerol would have 
maintained the enzyme in a solubilised state. Glycine 
acts as a protein stabilizing agent by preferential 
exclusion mechanism and thereby reducing the 
surface tension
33
. Glycerol is reported to enhance the 
thermodynamic stabilization of protein
34
 and pushes 
the hydrophobic region of a protein inside and thereby 
preventing inter-molecular interaction
35,36
. Probably, 
synergistic action of glycine and glycerol has 
maintained the solubility of mLOX in a solution state.  
Recombinant mLOX contains His tag in its  
N-terminal. Histidine residues have an affinity for 
copper, which might interfere with the activity of 
copper-dependent LOX. Hence, His tag was removed 
using endoprotease factor Xa and ascertained the 
activity of recombinant mLOX. Previous reports
31,32,37
 
which demonstrated the activity of LOX had retained 
the His tag. Hence, this is the first report where 
 
 
Fig. 6 — Intrinsic and extrinsic fluorescence of mLOX. (A) 
Tryptophan fluorescence emission spectrum of native and reduced 
recombinant mLOX. Recombinant mLOX (3 μM) was reduced 
with different concentrations of DTT (20-100 mM) at 60°C. 
Intrinsic fluorescence of mLOX was measured by exciting at the 
wavelength of 295 nm and emission spectrum was collected from 
300 to 370 nm with an interval of 1 nm. Inlet showing the 
emission at 304 nm of mLOX treated with a varing concentration 
of DTT; (B) ANSA binding - Extrinsic fluorescence of 
recombinant mLOX. Recombinant mLOX(3 μM)was reduced 
with 50 mM DTT at 60°C and denatured with 2 M GnHCl and 
then exposed to ANSA in 1:100 ratio of protein concentration. 
ANSA binding was assessed by exciting at 370 nm and emission 
spectrum was collected from 400-600 nm. Data shown represent 
mean from three independent experiments. (RFU –Relative 
Fluorescence Unit). 
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mLOX has been characterized without the presence of 
fusion tags. 
In our study, the pseudosubstrate DAP showed 
maximal activity when compared to the natural 
substrates. This might be due to the non-availablity of 
free peptidyl lysine in elastin and collagen. Our 
results also indicated that the recombinant mLOX 
showed maximum activity at pH 8.0. (Fig. 2B) which 
was in accordance with an earlier report on LOX, 
purified from the Dosidicus gigas, which had 
maximum activity between the pH 8 to 8.2
38
. It was 
reported that LOX oxidises basic globular proteins 
with a pI value of > 8.0 and not the neutral and acidic 
proteins
39
.  
Recombinant mLOX, showed maximal enzyme 
activity Vmax to be 1.25 Unit/mg (Units = µmoles of 
H2O2s
−1
), which was higher than the previous reports. 
Herwald et al. showed 0.31 Unit/mg (1 Unit = 1 nM 
of DAP/min) of recombinant LOX activity using 
amplex red assay
32
. whereas, Jung et al. purified LOX 
by cloning and showed activity of 0.097 Unit/mg  
(1 Unit = 1 μM of benzyl amine/min) using amine 
oxidase activity assay
31
. However, recombinant 
mLOX showed low affinity against the DAP  
(Km 3.72 × 10
−4
 M). whereas, Palamkumbura et al. 
determined Km for LOX towards DAP to be  
0.5 mM
40
. The possible reason for this difference may 
be due to the variation in enzyme sources where the 
present study used purified recombinant human 
mLOX, while the earlier study used LOX that was 
purified from bovine aorta. 
Immunofluorescence staining of collagen fibres  
in ARPE-19 cellsshowed increased collagen  
cross-linking in dose-dependent manner to 
exogenously added recombinant mLOX (Fig. 3C-F). 
Earlier Kothapalli et al.
41
 and Markris et al.
42
 reported 
exogenous addition of LOX increases cross-linking of 
elastin and collagen, respectively. The enhanced 
collagen bundles confer that recombinant mLOX is 
biologically active. Since recombinant mLOX is 
biologically active, it would be suitable for 
angiogenesis and other in vitro assays.  
Secondary structure analysis of mLOX by CD 
spectra indicated that the degree of secondary 
structure of the refolded mLOX (α-helix of 8.43% and 
β-strand of 22%) was in accordance with the 
secondary structure of our reported mLOX model 
(13.5% of α-Helix and 16.4% of β-Sheet)21. Our 
previously reported LOX model has a higher affinity 
for Hcys (−9.53 kcal/ mol) than the established inhibit 
or βAPN (−6.29 kcal/mol). Further, we discussed the 
nature of the catalytic cavity of LOX and its 
interacting residues with the substrate and inhibitors
21
. 
The present study shows that Hcys inhibits mLOX 
activity even at a lower concentration of 30 μM than 
βAPN, which inhibits LOX at  
400 μM. Thus, the secondary structure of refolded 
mLOX and the outcome of the inhibitor assay in  
the present study correlates with our reported  
in silico results. 
In the current study, enzymatic action of mLOX 
was observed even at 75°C which was in agreement 
with a study by Torres-Arreola et al. which showed 
LOX activity of Dosidicus gigas up to 70°C
38
. 
Correspondingly, the secondary structure of mLOX 
was found to be stable till 90°C as observed in the 
melting experiments using CD spectra (Fig. 5B & C). 
Hence, thermo-stable nature of LOX has been 
experimentally proved here.  
Chen et al. stated that disulfide bonds in LOX 
render rigidity and high resistance to denaturants
37
. To 
examine the rigid nature of LOX, we studied the 
intrinsic and extrinsic fluorescence of mLOX under 
native and disulfide reduced conditions. mLOX has  
3 tryptophan residues (at 286, 288 and 363 positions) 
among them 286
th
 and 288
th
 residues are present in the 
buried conserved copper-binding site. Tryptophan 
emission of mLOX resulted in heterogeneous 
emission with a major and minor fluorescence at  
304 nm and 333 nm respectively, (Fig. 6A). 
Heterogeneous emission arises when tryptophan 
residues in a protein are present in both buried and 
exposed region. On reduction of disulfide bonds in 
mLOX, tryptophan emission spectra showed a red 
shift in the lambda max from 304 to 307 nm with a 
fall in the quantum yield from 5000 RFU to  
2000 RFU (Fig. 6A). The red shift shows the 
unfolding and fall in quantum yield is due to the 
exposure of buried tryptophan residues. No significant 
change was observed with the minor peak at 333 nm. 
Hence, refolded mLOX possess tryptophan in its core 
as well as in surface of its structure. Our in silico 
report
21
 on LOX structure show tryptophan i.e. 286
th
 
and 288
th
 residues present in the buried region along 
with copper binding site and 363
rd
 tryptophan residue 
present at the exposed region. Similarly, ANSA 
exhibits higher fluorescence intensity when disulfide 
bonds are reduced compared to the native mLOX. 
Reduction of disulfide bond also favours the 
unfolding action of GnHCl. Hence, intrinsic and 
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extrinsic fluorescence experiments explain that 
disulfide bonds hold the structure and render 
resistance for LOX against temperature and 
denaturant. Similarly, Jana et al. demonstrated that 
the structure of streptomycin adenyl transferase is 
stabilized by disulfide bonds using tryptophan 
emission and ANSA binding analysis
43
. To the best of 
our knowledge, this is the first study on tryptophan 
localisation of LOX in its structure and explains 
disulfide bond involvement in the stability of LOX 
structure. 
In summary, the present work reports a buffer to 
maintain native mLOX enzyme in aqueous buffer 
without any aggregation. This buffer can facilitate 
elucidation of the crystal structure of LOX through 
crystallography studies. Intrinsic and extrinsic 
fluorescence data explains the stability of LOX under 
unusual conditions. Further, the biologically active 
mLOX can be utilized to understand the disease 
mechanism where LOX is implicated. 
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